Corcept Therapeutics Investigated for Securities Fraud

Probe follows report of FDA warnings against the pharmaceutical company.

Jan. 30, 2026 at 12:23pm

Got story updates? Submit your updates here. ›

Corcept Therapeutics, a pharmaceutical company based in Boston, is under investigation for securities fraud following a report that the U.S. Food and Drug Administration (FDA) had issued warnings against the company. The investigation is being conducted by the law firm Block & Leviton.

Why it matters

Allegations of securities fraud can have significant consequences for a publicly traded company like Corcept Therapeutics, potentially impacting investor confidence and the company's stock price. The FDA warnings also raise concerns about the company's compliance with regulations and the safety of its products.

The details

According to the report, the FDA had issued warnings to Corcept Therapeutics regarding its marketing and promotion of certain pharmaceutical products. The details of these warnings and the specific allegations of securities fraud are not yet publicly known, but the investigation by Block & Leviton suggests that the company may have misled investors or failed to properly disclose material information.

  • The investigation was announced on January 30, 2026.

The players

Corcept Therapeutics

A pharmaceutical company based in Boston, Massachusetts.

Block & Leviton

A law firm conducting the investigation into Corcept Therapeutics.

U.S. Food and Drug Administration (FDA)

The federal agency that issued warnings against Corcept Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

This investigation highlights the importance of pharmaceutical companies adhering to regulatory requirements and being transparent with investors. The outcome of the probe could have significant implications for Corcept Therapeutics and its stakeholders.